RecruitingNCT06931769

TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

Sponsor

The Netherlands Cancer Institute

Enrollment

100 participants

Start Date

Nov 6, 2025

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at seven time points during and after their anticancer treatment in a mobile application. For all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study in the Netherlands follows women with Stage III triple-negative breast cancer (a type that lacks hormone receptors and HER2) through their standard treatment — chemotherapy before surgery, surgery, and possibly more treatment after — to better understand outcomes and improve care guidelines. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with Stage III triple-negative breast cancer (no HER2, low estrogen and progesterone receptors) - You are scheduled to receive standard pre-surgery chemotherapy in the Netherlands - You are able to use a smartphone, tablet, or computer - You understand Dutch **You may NOT be eligible if...** - You have cancer that has spread to distant organs (metastatic) - You will only receive treatment after surgery (adjuvant-only approach) - You are enrolled in another trial with an active treatment intervention Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.